<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6067707</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0200816</article-id><article-id pub-id-type="publisher-id">PONE-D-17-41435</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Pharmaceutical Processing Technology</subject><subj-group><subject>Drug Synthesis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Addicts</subject><subj-group><subject>Drug Users</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Addicts</subject><subj-group><subject>Drug Users</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Infectious diseases</subject><subj-group><subject>Viral diseases</subject><subj-group><subject>HIV infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>HIV epidemiology</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Geographical Locations</subject><subj-group><subject>Asia</subject><subj-group><subject>China</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Population Groupings</subject><subj-group><subject>Sexuality Groupings</subject><subj-group><subject>Men WHO Have Sex with Men</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Sociology</subject><subj-group><subject>Education</subject><subj-group><subject>Educational Attainment</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Synthetic drug use and HIV infection among men who have sex with men in China: A sixteen-city, cross-sectional survey</article-title><alt-title alt-title-type="running-head">Synthetic drug use and HIV among MSM in China</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Luo</surname><given-names>Wei</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Hong</surname><given-names>Hang</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="author-notes" rid="currentaff001"><sup>&#x000a4;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xiaofang</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>McGoogan</surname><given-names>Jennifer M.</given-names></name><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rou</surname><given-names>Keming</given-names></name><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0839-4548</contrib-id><name><surname>Wu</surname><given-names>Zunyou</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People&#x02019;s Republic of China</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, California, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Hu</surname><given-names>Wenhui</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Lewis Katz School of Medicine at Temple University, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="current-aff" id="currentaff001"><label>&#x000a4;</label><p>Current address: Ningbo Center for Diseases Control and Prevention, Ningbo, People&#x02019;s Republic of China</p></fn><corresp id="cor001">* E-mail: <email>wuzy@263.net</email>, <email>wuzunyou@chinaaids.cn</email></corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>7</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>13</volume><issue>7</issue><elocation-id>e0200816</elocation-id><history><date date-type="received"><day>23</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>3</day><month>7</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 Luo et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Luo et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0200816.pdf"/><abstract><sec id="sec001"><title>Introduction</title><p>Increasing evidence suggests an association between synthetic drug use and HIV infection among men who have sex with men (MSM). The aim of this study was to evaluate synthetic drug use prevalence, describe characteristics of synthetic drug users, and investigate whether synthetic drug use is associated with HIV infection among Chinese MSM.</p></sec><sec id="sec002"><title>Methods</title><p>A cross-sectional survey was conducted in 16 Chinese cities among males &#x0003e;18 years old who reported having had sex with men in the prior 3 months, but did not already have a known HIV-positive serostatus. Participants were grouped according to lifetime synthetic drug use and characteristics were compared using Chi-square test. Determinants of HIV infection were assessed using univariate and multivariate regression.</p></sec><sec id="sec003"><title>Results</title><p>Among 3,135 participants, 1,249 reported lifetime synthetic drug use, for a prevalence of 39.8%. Nearly all users (96.3%) reported using inhaled alkyl nitrites (&#x0201c;poppers&#x0201d;). Synthetic drug users were more likely to be younger (&#x0003c;30 years, p&#x0003c;0.001), single (p&#x0003c;0.001), and more educated (p&#x0003c;0.001), and were more likely to engage in higher risk sexual behavior compared to non-drug users. Overall HIV prevalence was 7.8% (246/3,135). However, prevalence among synthetic drug users was 10.6% (132/246) compared to 6.0% (114/246) for non-drug users (p&#x0003c;0.001). Factors associated with an increased odds of HIV infection included inconsistent condom use with male partners (adjusted odds ratio [OR] = 2.18, 95% confidence interval [CI] = 1.64&#x02013;2.91) and synthetic drug use (adjusted OR = 2.04, CI = 1.56&#x02013;2.70).</p></sec><sec id="sec004"><title>Conclusion</title><p>Prevalence of synthetic drug use, especially poppers use, prevalence was high in our study, and users had 2-fold greater odds of HIV acquisition. It is clear that there is an urgent need for increased prevention, testing, and treatment interventions for this key, dual-risk population in China. Moreover, we call on the Chinese Government to consider regulating poppers so that users can be properly warned about their associated risks.</p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution>Chinese National Science and Technology Major Project on Prevention and Treatment of Major Infectious Diseases including AIDS and Viral Hepatitis</institution></funding-source><award-id>2012ZX10001-007</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0839-4548</contrib-id><name><surname>Wu</surname><given-names>Zunyou</given-names></name></principal-award-recipient></award-group><funding-statement>This study was supported by Chinese National Science and Technology Major Project on Prevention and Treatment of Major Infectious Diseases including AIDS and Viral Hepatitis (No.2012ZX10001-007) (ZW) (<ext-link ext-link-type="uri" xlink:href="http://www.most.gov.cn/kjjh/gjkjjh/">http://www.most.gov.cn/kjjh/gjkjjh/</ext-link>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="2"/><page-count count="13"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Certain key populations experience higher risk of human immunodeficiency virus (HIV) infection compared to the general population across all geographies, worldwide. For men who have sex with men (MSM), risk of HIV infection is 24-fold greater [<xref rid="pone.0200816.ref001" ref-type="bibr">1</xref>]. Stigma, discrimination, and violence associated with HIV infection cause this population to remain &#x0201c;hidden,&#x0201d; resulting in poorer uptake of HIV prevention, testing, treatment, and care, thereby creating a major, global public health challenge [<xref rid="pone.0200816.ref002" ref-type="bibr">2</xref>&#x02013;<xref rid="pone.0200816.ref004" ref-type="bibr">4</xref>].</p><p>Over the past three decades, researchers have consistently documented an array of sexual behaviors among MSM that have contributed to this key population&#x02019;s high risk for HIV infection[<xref rid="pone.0200816.ref003" ref-type="bibr">3</xref>]. However, new evidence from Europe [<xref rid="pone.0200816.ref005" ref-type="bibr">5</xref>], North America [<xref rid="pone.0200816.ref006" ref-type="bibr">6</xref>], Australia [<xref rid="pone.0200816.ref007" ref-type="bibr">7</xref>], and Asia [<xref rid="pone.0200816.ref008" ref-type="bibr">8</xref>], suggests that drug use is further elevating the risk for HIV infection for this vulnerable population [<xref rid="pone.0200816.ref009" ref-type="bibr">9</xref>&#x02013;<xref rid="pone.0200816.ref011" ref-type="bibr">11</xref>]. While drug use among MSM has historically involved the use of stimulants (e.g., ecstasy) or dissociatives (e.g., ketamine), other synthetic drugs such as methamphetamine, mephedrone, and alkyl nitrites (so-called &#x0201c;poppers&#x0201d;) are becoming more popular since users tend to experience both stimulant and sexual effects&#x02014;disinhibition and euphoria combined with enhanced libido, arousal, and pleasure[<xref rid="pone.0200816.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0200816.ref010" ref-type="bibr">10</xref>].</p><p>In China, both the drug use and HIV epidemics have continued to grow at a rapid rate. The number of drug users registered with the Chinese Government doubled from 2010, to nearly 3 million in 2014. However, the actual number was estimated to be more than 14 million in 2014. The variety of drugs used is also expanding from the traditional opium and heroin to amphetamine-type stimulants (e.g., methamphetamine) and new psychoactive substances (e.g., poppers). The prevalence of synthetic drug use among registered drug users in China exceeded that of heroin and opium use for the first time in 2014[<xref rid="pone.0200816.ref012" ref-type="bibr">12</xref>]. As for China&#x02019;s HIV epidemic, in 2015, a total of 574,000 people had been diagnosed with HIV infection, yet an additional 275,000 people were estimated to have HIV infection but still be unaware of it. The numbers of new infections are rising, with over 115,000 newly-diagnosed infections in 2015 alone [<xref rid="pone.0200816.ref013" ref-type="bibr">13</xref>]. Furthermore, the key population with the most rapidly growing HIV prevalence is MSM&#x02014;roughly 1.5% in 2005, 6% in 2010, and 8% in 2015[<xref rid="pone.0200816.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0200816.ref014" ref-type="bibr">14</xref>]. Although the intersection of the two epidemics began with unsafe injecting behavior among heroin users in rural southwestern China [<xref rid="pone.0200816.ref013" ref-type="bibr">13</xref>], a new overlap has developed&#x02014;high-risk sexual behavior among MSM who use synthetic drugs in China&#x02019;s cities.</p><p>Several studies have sought to examine this issue [<xref rid="pone.0200816.ref015" ref-type="bibr">15</xref>&#x02013;<xref rid="pone.0200816.ref021" ref-type="bibr">21</xref>], but most have been limited by their small sample sizes and/or geographical settings. Therefore, our aim was to evaluate the prevalence of synthetic drug use, to describe the characteristics of people who use synthetic drugs, and to investigate whether synthetic drug use was associated with HIV infection among a large sample of MSM across 16 cities in China. For the purposes of this study, we defined synthetic drugs as including ecstasy; ketamine; methamphetamine; Magu, which is a mix of methamphetamine and caffeine; and alkyl nitrite inhalants, also known as poppers. This group of drugs is often referred to by other terms such as &#x0201c;recreational drugs&#x0201d; or &#x0201c;club drugs.&#x0201d;</p></sec><sec sec-type="materials|methods" id="sec006"><title>Materials and methods</title><sec id="sec007"><title>Study design and setting</title><p>A cross-sectional study was conducted in 16 Chinese cities (Beijing, Tianjin, Changchun, Harbin, Shanghai, Nanjing, Hangzhou, Wuhan, Guangzhou, Shenzhen, Nanning, Chengdu, Chongqing, Kunming, Xi&#x02019;an, and Wulumuqi) from July to September 2015. <xref ref-type="fig" rid="pone.0200816.g001">Fig 1</xref> contains a flow diagram depicting the study design.</p><fig id="pone.0200816.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0200816.g001</object-id><label>Fig 1</label><caption><title>Flow diagram depicting the design of the cross-sectional study conducted among MSM in China.</title><p>A 39.8% lifetime synthetic drug use prevalence was observed. Overall HIV prevalence was 7.8%, with a higher prevalence among those who had used synthetic drugs in their lifetimes (10.6%) compared to those who had never used these drugs (6.0%).</p></caption><graphic xlink:href="pone.0200816.g001"/></fig><p>Study cities were selected based upon their having strong MSM community-based organizations (CBOs) that were providing HIV counseling and testing services at the time of the study. The largest MSM CBO in each selected city was chosen as that city&#x02019;s study site.</p></sec><sec id="sec008"><title>Participants</title><p>Attendees of study CBOs were screened for study participation. Eligibility criteria were: (1) being male, (2) being &#x0003e;18 years of age, and (3) having had anal sex with at least one male partner in the 3 months prior. Potential participants who met these criteria, but who had a known HIV-positive serostatus were excluded from the study. Individuals with diagnosed HIV infection were excluded from the study because awareness of HIV-positive serostatus may have influenced their HIV-related risk behavior, confounding our ability to investigate whether synthetic drug use was associated with HIV infection.</p></sec><sec id="sec009"><title>Sample size</title><p>Target sample size was calculated using the formula, <inline-formula id="pone.0200816.e001"><alternatives><graphic xlink:href="pone.0200816.e001.jpg" id="pone.0200816.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:mi>n</mml:mi><mml:mspace width="2pt"/><mml:mo>=</mml:mo><mml:mspace width="2pt"/><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>u</mml:mi></mml:mrow><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>u</mml:mi></mml:mrow><mml:mrow><mml:mi>&#x003b2;</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>&#x000d7;</mml:mo><mml:mn>4</mml:mn><mml:msub><mml:mrow><mml:mi>&#x003c0;</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>&#x003c0;</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>&#x003c0;</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>&#x003c0;</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:math></alternatives></inline-formula>, where <italic>&#x003b1;</italic> = 0.05, <italic>&#x003b2;</italic> = 0.1, <italic>u</italic><sub><italic>&#x003b1;</italic></sub> = 1.64, <italic>u</italic><sub><italic>&#x003b2;</italic></sub> = 1.28, and <italic>&#x003c0;</italic><sub>1</sub> and <italic>&#x003c0;</italic><sub>2</sub> were HIV prevalence rates among MSM who used drugs and MSM who did not. We assumed that <italic>&#x003c0;</italic><sub>1</sub> = 10%, <italic>&#x003c0;</italic><sub>2</sub> = 5%, and therefore <inline-formula id="pone.0200816.e002"><alternatives><graphic xlink:href="pone.0200816.e002.jpg" id="pone.0200816.e002g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M2"><mml:msub><mml:mrow><mml:mi>&#x003c0;</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mspace width="2pt"/><mml:mo>=</mml:mo><mml:mspace width="2pt"/><mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>&#x003c0;</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>&#x003c0;</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:mspace width="2pt"/><mml:mo>=</mml:mo><mml:mspace width="2pt"/><mml:mn>7.5</mml:mn><mml:mi>%</mml:mi></mml:math></alternatives></inline-formula>. Using this formula, we determined that a sample size of 946 would be required to detect a statistically significant difference between two groups (473 each). However, we estimated that the proportion of MSM who had used synthetic drugs in their lifetimes was approximately 25%, which elevated our sample size requirement to 1,900. We further assumed a participation refusal rate of 10%, again increasing our sample size requirement, this time to 2,100.</p></sec><sec id="sec010"><title>Face-to-face interviews</title><p>All interviews were conducted face-to-face in a private room at CBO offices by trained CBO staff members using a structured questionnaire. The questionnaire was intended to collect information from participants on demographic, sexual behavior (in the prior 3 months), and drug use behavior (lifetime) characteristics. The term synthetic drugs was defined for participants as including ecstasy, ketamine, methamphetamine, Magu, and &#x0201c;poppers.&#x0201d; Participants were allowed to respond freely to all demographic, sexual behavior history, and drug use behavior history questions. No pre-determined answer choices were offered, and answers were not independently verified. After each interview was completed, interviewers coded responses into categories for each variable.</p></sec><sec id="sec011"><title>Specimen collection and laboratory testing</title><p>Each participant was asked to provide a single 5 mL specimen of venous blood for HIV testing at the time of their interview. All specimens were collected by a trained nurse and stored at room temperature until centrifuged (within 12 hours of collection) to harvest serum. All serum samples were cryopreserved immediately for later HIV testing. Laboratory testing was performed at municipal HIV reference laboratories in compliance with China&#x02019;s National HIV Testing Guidelines [<xref rid="pone.0200816.ref022" ref-type="bibr">22</xref>]. HIV screening was first conducted by ELISA (Kehua Biotech Co. Ltd, Shanghai, China) and reactive samples were re-tested by two ELISAs (Kehua Biotech Co. Ltd, Shanghai, China and Acon Biotech Co. Ltd, Hangzhou, China) run in parallel. Confirmatory testing by Western blot (Genelabs Diagnostics, Singapore) was conducted on all samples yielding at least one positive ELISA result. All participants were notified of their results and given post-test counseling by trained CBO staff. All HIV-positive participants were referred to treatment.</p></sec><sec id="sec012"><title>Statistical analysis</title><p>Categorical variables were presented as number and percent. Prevalence of synthetic drug use was calculated by the number of participants reporting lifetime use (numerator) divided by the total number of participants (denominator). Similarly, HIV prevalence was calculated by the number of participants with HIV-positive serostatus divided by the total participants. Both were expressed as percentages. Participants were grouped according to whether they had or had not used synthetic drugs in their lifetimes. Characteristics of participants in these two subgroups (users versus non-users) were compared using Chi-square test.</p><p>Multiple logistic regression was used to investigate whether synthetic drug use was associated with HIV infection, controlling for potential confounding factors including demographic characteristics and risk behaviors. Demographic characteristics included Age (&#x02265;30 years vs &#x0003c;30 years as the reference), Ethnicity (Other vs Han as the reference), Marital Status (Married/cohabitating, Divorced/widowed vs Single as the reference), Education Level (&#x02265;College vs &#x02264;High school as the reference), Monthly Income (&#x02265;CNY 3,000 vs &#x0003c;CNY 3,000 as the reference). Risk behaviors included Frequency of Male-Male Sexual Behaviors (&#x02265;1 time per week vs &#x0003c;1 time per week as the reference), Number of Male Sexual Partners (&#x02265;2 vs 1 as the reference), Participated in Male Group Sex (No vs Yes as the reference), Duration of Penetrative Sexual Behavior (&#x02265;20 minutes vs &#x0003c;20 minutes as the reference), Consistent Condom Use with Male Partners (No vs Yes as the reference), Synthetic Drug User (Yes vs No as the reference).</p><p>All variables were included in the univariate analysis. Variables found to have significance in the univariate analysis were included in the multiple logistic regression. In addition, variables not found to have significance in the univariate analysis, but were believed to be important were also included in the final multivariate logistic regression model. A stepwise algorithm was used to select variables to enter and remain in the model, where the SLENTRY = 0.05 (i.e., only variables being significant at the 0.05 level can be added to the model) and the SLSTAY = 0.15 (i.e., variables being significant at the 0.15 level can remain in the model).</p><p>All confidence intervals (CIs) presented were 95% CIs. All p-values were 2-sided. P-values less than 0.05 were considered statistically significant. Data were double entered and verified using EpiData software (Version 3.0, The Epidata Association, Denmark). Data analyses were performed using SAS software (Version 9.1, SAS Institute, USA).</p></sec><sec id="sec013"><title>Ethical considerations</title><p>The study protocol was reviewed and approved by the Institutional Review Board of the National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention. Written informed consent was obtained from all participants prior to enrollment. All data collected, including HIV test results, were kept confidential. Each participant was compensated CNY 30 (approximately USD 5).</p></sec></sec><sec id="sec014"><title>Results and discussion</title><sec id="sec015"><title>Participants</title><p>As shown in <xref ref-type="fig" rid="pone.0200816.g001">Fig 1</xref>, a total of 3,156 individuals seeking HIV counseling and testing services at selected CBOs in the 16 cities were screened for study participation. Among those screened, 12 failed to meet inclusion criteria and 9 were excluded due to known HIV-positive serostatus. Thus, a total of 3,135 (99.3%) enrolled in the study, and all completed the questionnaire and HIV testing.</p><p>Characteristics of study participants are shown in <xref rid="pone.0200816.t001" ref-type="table">Table 1</xref>. A majority of participants were younger than 30 years of age (58.1%), were of a Han ethnicity (91.4%), were single (72.2%), had an education level of college or above (61.7%), and reported earning a monthly income of at least CNY 3,000 (approximately USD 430; 63.9%). In terms of sexual behavior, a majority of participants reported having engaged in male-male sexual behaviors less than once per week (61.0%), having more than one male sexual partner (56.6%), not participating in male group sex (95.0%), having penetrative sexual behavior durations of &#x02265;20 minutes (57.5%), and inconsistently using condoms with male sexual partners (53.3%). A total of 246 participants (of 3,135) were found to have an HIV-positive serostatus, for an overall study population HIV prevalence of 7.8%.</p><table-wrap id="pone.0200816.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0200816.t001</object-id><label>Table 1</label><caption><title>Characteristics of all participants, and participants grouped by lifetime synthetic drug use.</title></caption><alternatives><graphic id="pone.0200816.t001g" xlink:href="pone.0200816.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Variables</th><th align="center" rowspan="2" colspan="1">All Participants<break/>N (%)</th><th align="center" colspan="4" rowspan="1">Synthetic Drug<xref ref-type="table-fn" rid="t001fn001"><sup>a</sup></xref> User Subgroup Comparison</th></tr><tr><th align="center" rowspan="1" colspan="1">Non-User<break/>n (%)</th><th align="center" rowspan="1" colspan="1">User<break/>n (%)</th><th align="center" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> Value</th><th align="center" rowspan="1" colspan="1">P-Value<xref ref-type="table-fn" rid="t001fn002"><sup>b</sup></xref></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Overall</bold></td><td align="center" rowspan="1" colspan="1">3,135 (100)</td><td align="center" rowspan="1" colspan="1">1,886 (100)</td><td align="center" rowspan="1" colspan="1">1,249 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Age</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;30 years</td><td align="center" rowspan="1" colspan="1">1,822 (58.1)</td><td align="center" rowspan="1" colspan="1">991 (52.5)</td><td align="center" rowspan="1" colspan="1">831 (66.5)</td><td align="char" char="." rowspan="1" colspan="1">60.4</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;30 years</td><td align="center" rowspan="1" colspan="1">1,313 (41.8)</td><td align="center" rowspan="1" colspan="1">895 (47.5)</td><td align="center" rowspan="1" colspan="1">418 (33.5)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Ethnicity</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Han</td><td align="center" rowspan="1" colspan="1">2,864 (91.4)</td><td align="center" rowspan="1" colspan="1">1,730 (91.7)</td><td align="center" rowspan="1" colspan="1">1,134 (90.8)</td><td align="char" char="." rowspan="1" colspan="1">0.8</td><td align="char" char="." rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Other</td><td align="center" rowspan="1" colspan="1">271 (8.6)</td><td align="center" rowspan="1" colspan="1">156 (8.3)</td><td align="center" rowspan="1" colspan="1">115 (9.2)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Marital Status</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Single</td><td align="center" rowspan="1" colspan="1">2,264 (72.2)</td><td align="center" rowspan="1" colspan="1">1,271 (67.4)</td><td align="center" rowspan="1" colspan="1">993 (79.5)</td><td align="char" char="." rowspan="1" colspan="1">55.3</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Married/cohabitating</td><td align="center" rowspan="1" colspan="1">731 (23.3)</td><td align="center" rowspan="1" colspan="1">513 (27.2)</td><td align="center" rowspan="1" colspan="1">218 (17.5)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Divorced/widowed</td><td align="center" rowspan="1" colspan="1">140 (4.5)</td><td align="center" rowspan="1" colspan="1">102 (5.4)</td><td align="center" rowspan="1" colspan="1">38 (3.0)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Education Level</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02264;High school</td><td align="center" rowspan="1" colspan="1">1,202 (38.3)</td><td align="center" rowspan="1" colspan="1">784 (41.6)</td><td align="center" rowspan="1" colspan="1">418 (33.5)</td><td align="char" char="." rowspan="1" colspan="1">20.9</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;College</td><td align="center" rowspan="1" colspan="1">1,933 (61.7)</td><td align="center" rowspan="1" colspan="1">1,102 (58.4)</td><td align="center" rowspan="1" colspan="1">831 (66.5)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Monthly Income</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;CNY 3,000</td><td align="center" rowspan="1" colspan="1">1,132 (36.1)</td><td align="center" rowspan="1" colspan="1">697 (37.0)</td><td align="center" rowspan="1" colspan="1">435 (34.8)</td><td align="char" char="." rowspan="1" colspan="1">1.5</td><td align="char" char="." rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;CNY 3,000</td><td align="center" rowspan="1" colspan="1">2,003 (63.9)</td><td align="center" rowspan="1" colspan="1">1,189 (63.0)</td><td align="center" rowspan="1" colspan="1">814 (65.2)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="2" rowspan="1"><bold>Frequency of Male-Male Sexual Behaviors</bold></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;1 time per week</td><td align="center" rowspan="1" colspan="1">1,912 (61.0)</td><td align="center" rowspan="1" colspan="1">1,211 (64.2)</td><td align="center" rowspan="1" colspan="1">701 (56.1)</td><td align="char" char="." rowspan="1" colspan="1">19.9</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;1 time per week</td><td align="center" rowspan="1" colspan="1">1,220 (38.9)</td><td align="center" rowspan="1" colspan="1">675 (35.8)</td><td align="center" rowspan="1" colspan="1">545 (43.7)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Missing</td><td align="center" rowspan="1" colspan="1">3 (0.1)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">3 (0.2)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="2" rowspan="1"><bold>Number of Male Sexual Partners</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1</td><td align="center" rowspan="1" colspan="1">1,358 (43.3)</td><td align="center" rowspan="1" colspan="1">918 (48.7)</td><td align="center" rowspan="1" colspan="1">440 (35.2)</td><td align="char" char="." rowspan="1" colspan="1">54.5</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;2</td><td align="center" rowspan="1" colspan="1">1,774 (56.6)</td><td align="center" rowspan="1" colspan="1">968 (51.3)</td><td align="center" rowspan="1" colspan="1">806 (64.5)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Missing</td><td align="center" rowspan="1" colspan="1">3 (0.1)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">3 (0.2)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="2" rowspan="1"><bold>Participated in Male Group Sex</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" rowspan="1" colspan="1">153 (4.9)</td><td align="center" rowspan="1" colspan="1">61 (3.2)</td><td align="center" rowspan="1" colspan="1">92 (7.4)</td><td align="char" char="." rowspan="1" colspan="1">27.8</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td align="center" rowspan="1" colspan="1">2,979 (95.0)</td><td align="center" rowspan="1" colspan="1">1,825 (96.8)</td><td align="center" rowspan="1" colspan="1">1,154 (92.4)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Missing</td><td align="center" rowspan="1" colspan="1">3 (0.1)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">3 (0.2)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="2" rowspan="1"><bold>Duration of Penetrative Sexual Behavior</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;20 minutes</td><td align="center" rowspan="1" colspan="1">1,321 (42.1)</td><td align="center" rowspan="1" colspan="1">894 (47.4)</td><td align="center" rowspan="1" colspan="1">427 (34.2)</td><td align="char" char="." rowspan="1" colspan="1">56.1</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;20 minutes</td><td align="center" rowspan="1" colspan="1">1,802 (57.5)</td><td align="center" rowspan="1" colspan="1">980 (52.0)</td><td align="center" rowspan="1" colspan="1">822 (65.8)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Missing</td><td align="center" rowspan="1" colspan="1">12 (0.4)</td><td align="center" rowspan="1" colspan="1">12 (0.6)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="2" rowspan="1"><bold>Consistent Condom Use with Male Partners</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" rowspan="1" colspan="1">1,460 (46.6)</td><td align="center" rowspan="1" colspan="1">906 (48.0)</td><td align="center" rowspan="1" colspan="1">554 (44.3)</td><td align="char" char="." rowspan="1" colspan="1">4.2</td><td align="char" char="." rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td align="center" rowspan="1" colspan="1">1,671 (53.3)</td><td align="center" rowspan="1" colspan="1">977 (51.8)</td><td align="center" rowspan="1" colspan="1">694 (55.6)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Missing</td><td align="center" rowspan="1" colspan="1">4 (0.1)</td><td align="center" rowspan="1" colspan="1">3 (0.2)</td><td align="center" rowspan="1" colspan="1">1 (0.1)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>HIV Serostatus</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Positive</td><td align="center" rowspan="1" colspan="1">246 (7.8)</td><td align="center" rowspan="1" colspan="1">114 (6.0)</td><td align="center" rowspan="1" colspan="1">132 (10.6)</td><td align="char" char="." rowspan="1" colspan="1">21.3</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Negative</td><td align="center" rowspan="1" colspan="1">2,889 (92.2)</td><td align="center" rowspan="1" colspan="1">1,772 (94.0)</td><td align="center" rowspan="1" colspan="1">1,117 (89.4)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><sup>a</sup>The term &#x0201c;synthetic drug&#x0201d; included ecstasy, ketamine, methamphetamine, Magu (combination of methamphetamine and caffeine), and &#x0201c;poppers&#x0201d; (inhaled alkyl nitrites).</p></fn><fn id="t001fn002"><p><sup>b</sup>Subgroups were compared using &#x003c7;<sup>2</sup> test to generate p-values listed.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec016"><title>Synthetic drug users versus non-users</title><p>While 1,886 participants (of 3,135, 60.2%) reported never having used synthetic drugs in their lifetimes, a total of 1,249 had used synthetic drugs at least once before, for an overall lifetime synthetic drug use prevalence of 39.8% (<xref ref-type="fig" rid="pone.0200816.g001">Fig 1</xref>). Among those who reported having used synthetic drugs in their lifetimes, 96.3% (1,203/1,249) reported having used poppers and 3.7% (46/1,203) reported having used other synthetic drugs such as methamphetamine, ketamine, ecstasy, and Magu (data not shown).</p><p>A comparison of these two groups is presented in <xref rid="pone.0200816.t001" ref-type="table">Table 1</xref>. A greater proportion of synthetic drug users were young (&#x0003c;30 years, &#x003c7;<sup>2</sup> = 60.4, p&#x0003c;0.001), single (&#x003c7;<sup>2</sup> = 55.3, p&#x0003c;0.001), and had at least some college education (&#x003c7;<sup>2</sup> = 20.9, p&#x0003c;0.001), compared to non-users. A greater proportion of synthetic drug users reported having engaged in male-male sexual behavior more than once per week (&#x003c7;<sup>2</sup> = 19.9, p&#x0003c;0.001), having had more than one male sexual partner (&#x003c7;<sup>2</sup> = 54.5, p&#x0003c;0.001), having participated in male group sex (&#x003c7;<sup>2</sup> = 27.8, p&#x0003c;0.001), and having had penetrative sexual behavior durations of &#x02265;20 minutes (&#x003c7;<sup>2</sup> = 56.1, p&#x0003c;0.001), and having consistently used condoms with male partners (&#x003c7;<sup>2</sup> = 4.2, p = 0.04), compared to non-users. Finally, compared to non-users, a greater proportion of synthetic users had an HIV-positive serostatus (&#x003c7;<sup>2</sup> = 21.3, p&#x0003c;0.001).</p></sec><sec id="sec017"><title>Factors associated with HIV-positive serostatus</title><p><xref rid="pone.0200816.t002" ref-type="table">Table 2</xref> presents the characteristics of the 246 participants diagnosed with HIV infection as well as factors associated with HIV-positive serostatus. Among these 246 participants, a majority was &#x0003c;30 years old (60.1%), of Han ethnicity (93.0%), single (68.7%), had education levels of college or above (50.8%), and reported monthly incomes of at least CNY 3,000 (approximately USD 430; 64.2%). Most reported having engaged in male-male sexual behaviors less than once per week (69.1%), having had more than one male sexual partner (58&#x000b7;1%), not having participated in male group sex (93.9%), having had penetrative sexual behavior durations of &#x02265;20 minutes (63.0%), and having inconsistently used condoms with male sexual partners (69.5%). A majority of participants diagnosed with HIV infection had also used synthetic drugs in their lifetimes (53.7%).</p><table-wrap id="pone.0200816.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0200816.t002</object-id><label>Table 2</label><caption><title>Results of univariate and multivariate regression models predicting factors associated with HIV-positive serostatus.</title></caption><alternatives><graphic id="pone.0200816.t002g" xlink:href="pone.0200816.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">HIV-Positive Serostatus<break/>N (%)</th><th align="center" rowspan="1" colspan="1">Unadjusted<break/>OR (CI)</th><th align="center" rowspan="1" colspan="1">P-value<xref ref-type="table-fn" rid="t002fn002"><sup>a</sup></xref></th><th align="center" rowspan="1" colspan="1">Adjusted<break/>OR (CI)</th><th align="center" rowspan="1" colspan="1">P-value<xref ref-type="table-fn" rid="t002fn002"><sup>a</sup></xref></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Overall</bold></td><td align="center" rowspan="1" colspan="1">246 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Age</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;30 years</td><td align="center" rowspan="1" colspan="1">148 (60.1)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;30 years</td><td align="center" rowspan="1" colspan="1">98 (39.8)</td><td align="center" rowspan="1" colspan="1">0.91 (0.70&#x02013;1.19)</td><td align="char" char="." rowspan="1" colspan="1">0.50</td><td align="center" rowspan="1" colspan="1">0.77 (0.56&#x02013;1.07)</td><td align="char" char="." rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Ethnicity</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Han</td><td align="center" rowspan="1" colspan="1">229 (93.0)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Other</td><td align="center" rowspan="1" colspan="1">17 (6.9)</td><td align="center" rowspan="1" colspan="1">0.77 (0.46&#x02013;1.28)</td><td align="char" char="." rowspan="1" colspan="1">0.32</td><td align="center" rowspan="1" colspan="1">0.72 (0.43&#x02013;1.23)</td><td align="char" char="." rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Marital Status</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Single</td><td align="center" rowspan="1" colspan="1">169 (68.7)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Married/cohabitating</td><td align="center" rowspan="1" colspan="1">68 (27.6)</td><td align="center" rowspan="1" colspan="1">1.27 (0.95&#x02013;1.71)</td><td align="char" char="." rowspan="1" colspan="1">0.11</td><td align="center" rowspan="1" colspan="1">1.37 (0.97&#x02013;1.95)</td><td align="char" char="." rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Divorced/widowed</td><td align="center" rowspan="1" colspan="1">9 (3.7)</td><td align="center" rowspan="1" colspan="1">0.85 (0.43&#x02013;1.70)</td><td align="char" char="." rowspan="1" colspan="1">0.65</td><td align="center" rowspan="1" colspan="1">0.86 (0.41&#x02013;1.82)</td><td align="char" char="." rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Education Level</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02264;High school</td><td align="center" rowspan="1" colspan="1">121 (49.2)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;College</td><td align="center" rowspan="1" colspan="1">125 (50.8)</td><td align="center" rowspan="1" colspan="1">0.62 (0.48&#x02013;0.80)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">0.54 (0.41&#x02013;0.71)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Monthly Income</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;CNY 3,000</td><td align="center" rowspan="1" colspan="1">88 (35.8)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;CNY 3,000</td><td align="center" rowspan="1" colspan="1">158 (64.2)</td><td align="left" rowspan="1" colspan="1">1.02 (0.77&#x02013;1.33)</td><td align="char" char="." rowspan="1" colspan="1">0.91</td><td align="center" rowspan="1" colspan="1">1.08 (0.81&#x02013;1.43)</td><td align="char" char="." rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" colspan="2" rowspan="1"><bold>Frequency of Male-Male Sexual Behaviors</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;1 time per week</td><td align="center" rowspan="1" colspan="1">170 (69.1)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;1 time per week</td><td align="center" rowspan="1" colspan="1">76 (30.9)</td><td align="center" rowspan="1" colspan="1">0.68 (0.51&#x02013;0.90)</td><td align="char" char="." rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1">0.55 (0.41&#x02013;0.73)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" colspan="2" rowspan="1"><bold>Number of Male Sexual Partners</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1</td><td align="center" rowspan="1" colspan="1">103 (41.9)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;2</td><td align="center" rowspan="1" colspan="1">143 (58.1)</td><td align="center" rowspan="1" colspan="1">1.07 (0.82&#x02013;1.39)</td><td align="char" char="." rowspan="1" colspan="1">0.62</td><td align="center" rowspan="1" colspan="1">0.93 (0.70&#x02013;1.24)</td><td align="char" char="." rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" colspan="2" rowspan="1"><bold>Participated in Male Group Sex</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" rowspan="1" colspan="1">15 (6.1)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td align="center" rowspan="1" colspan="1">231 (93.9)</td><td align="center" rowspan="1" colspan="1">0.78 (0.45&#x02013;1.33)</td><td align="char" char="." rowspan="1" colspan="1">0.36</td><td align="center" rowspan="1" colspan="1">0.90 (0.50&#x02013;1.60)</td><td align="char" char="." rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" colspan="2" rowspan="1"><bold>Duration of Penetrative Sexual Behavior</bold> behavior</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;20 minutes</td><td align="center" rowspan="1" colspan="1">89 (36.2)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;20 minutes</td><td align="center" rowspan="1" colspan="1">155 (63.0)</td><td align="center" rowspan="1" colspan="1">1.30 (0.99&#x02013;1.71)</td><td align="char" char="." rowspan="1" colspan="1">0.06</td><td align="center" rowspan="1" colspan="1">1.21 (0.92&#x02013;1.60)</td><td align="char" char="." rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Missing</td><td align="center" rowspan="1" colspan="1">2 (0.8)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="2" rowspan="1"><bold>Consistent Condom Use with Male Partners</bold> sex with male</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" rowspan="1" colspan="1">75 (30.5)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td align="center" rowspan="1" colspan="1">171 (69.5)</td><td align="center" rowspan="1" colspan="1">2.10 (1.59&#x02013;2.78)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">2.18 (1.64&#x02013;2.91)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Synthetic Drug</bold><xref ref-type="table-fn" rid="t002fn003"><sup>b</sup></xref>
<bold>User</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td align="center" rowspan="1" colspan="1">114 (46.3)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" rowspan="1" colspan="1">132 (53.7)</td><td align="center" rowspan="1" colspan="1">1.85 (1.41&#x02013;2.38)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">2.04 (1.56&#x02013;2.70)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>OR: odds ratio; CI: 95% confidence interval.</p></fn><fn id="t002fn002"><p><sup>a</sup>ORs, CIs, and p-values generated based on univariate and multivariate logistic regression model.</p></fn><fn id="t002fn003"><p><sup>b</sup>The term &#x0201c;synthetic drug&#x0201d; included ecstasy, ketamine, methamphetamine, Magu (combination of methamphetamine and caffeine), and &#x0201c;poppers&#x0201d; (inhaled alkyl nitrites).</p></fn></table-wrap-foot></table-wrap><p>After controlling for possible confounding factors, multivariate regression analysis revealed two factors associated with higher odds of HIV-positive serostatus: inconsistent condom use with male partners (adjusted OR = 2.18, CI = 1.64&#x02013;2.91) and lifetime synthetic drug use (adjusted OR = 2.04, CI = 1.56&#x02013;2.70). Two factors were found to be protective: higher educational attainment (&#x02265;college: adjusted OR = 0.54, CI = 0.41&#x02013;0.71) and higher frequency of male-male sexual behaviors (&#x02265;1 time per week: adjusted OR = 0.55, CI = 0.41&#x02013;0.73, <xref rid="pone.0200816.t002" ref-type="table">Table 2</xref>).</p></sec><sec id="sec018"><title>Interpretations</title><p>Our main findings were an overall lifetime synthetic drug use prevalence of 39.8% among the 3,156 MSM surveyed across 16 cities in China. Synthetic drug users were more likely to be young, single, and better educated, and were more likely to engage in higher risk sexual behavior compared to non-users. HIV prevalence among synthetic drug users was 10.6%, well above that of non-users (6.0%), and odds of HIV-positive serostatus was 2-fold higher among synthetic drug users, compared to non-users.</p><p>Our finding of nearly 40% prevalence of lifetime synthetic drug use was higher than the 23% observed in a 2011 study in Shenyang,[<xref rid="pone.0200816.ref020" ref-type="bibr">20</xref>] and the 28% observed in a 2013 study in seven cities (Shanghai, Nanjing, Changsha, Zhengzhou, Ji&#x02019;nan, Shenyang, and Kunming) [<xref rid="pone.0200816.ref021" ref-type="bibr">21</xref>]. However, our study, using more recent data from a larger sample and a broader geography, may have produced both a more representative and generalizable estimate. Furthermore, other studies published to date have examined only recent synthetic drug use (in the prior 3, 6, or 12 months) [<xref rid="pone.0200816.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0200816.ref017" ref-type="bibr">17</xref>&#x02013;<xref rid="pone.0200816.ref019" ref-type="bibr">19</xref>], which likely underestimated of the size of the synthetic drug-using MSM population in China.</p><p>We found that inhaled alkyl nitrites, or poppers, was by far the most commonly used synthetic drug among the participants in our study (96% of users reported popper use). This puts prevalence of lifetime poppers use in our study at 38%, similar to the 47% lifetime popper use prevalence among MSM in Beijing observed in a 2012 study [<xref rid="pone.0200816.ref016" ref-type="bibr">16</xref>]. Poppers have previously been identified as the most popular synthetic drug among Chinese MSM in several studies [<xref rid="pone.0200816.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0200816.ref017" ref-type="bibr">17</xref>&#x02013;<xref rid="pone.0200816.ref020" ref-type="bibr">20</xref>]. This is likely due, at least in part, to their still-legal status, ubiquitous availability, and low cost. However, it has also been attributed to the relaxation effect poppers have on rectal muscle, which reduces pain during sex. Thus, poppers provide the stimulant and sexual effects of other synthetic drugs (i.e., euphoria, disinhibition, enhanced libido, arousal, pleasure), and more, all for less money, added convenience, and no legal risk [<xref rid="pone.0200816.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0200816.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0200816.ref020" ref-type="bibr">20</xref>]. Finally, since poppers are legal, heavily marketed with colorful packaging, and are not labeled like drugs, carrying no visible warnings about their risks, users do not consider them dangerous.</p><p>Several studies of synthetic drug use among MSM in China have, similar to our findings, reported that MSM users of synthetic drugs tend to be young and single [<xref rid="pone.0200816.ref015" ref-type="bibr">15</xref>&#x02013;<xref rid="pone.0200816.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0200816.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0200816.ref020" ref-type="bibr">20</xref>]. and have higher levels of educational attainment [<xref rid="pone.0200816.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0200816.ref017" ref-type="bibr">17</xref>]. Furthermore, several studies support our finding of increased high-risk sexual behavior among synthetic drug users compared to non-users&#x02014;users being more likely to have increased numbers of male sex partners, engage in commercial sex and group sex, and have unprotected sex [<xref rid="pone.0200816.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0200816.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0200816.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0200816.ref020" ref-type="bibr">20</xref>].</p><p>Similarly, our finding of higher HIV prevalence among synthetic drug users (10.6% compared to 6.0% among non-users) and 2-fold greater odds of HIV infection among synthetic drug users is also supported by the existing literature. A 2009 study among MSM in Changsha (n = 826) found HIV prevalence of 19% among users versus 11% among non-users and 2-fold greater odds of HIV infection among users [<xref rid="pone.0200816.ref019" ref-type="bibr">19</xref>]. In a 2011 study in Shenyang (n = 625) HIV prevalence was higher among users (20% versus 7%) and users had 3.5-fold greater odds of HIV infection [<xref rid="pone.0200816.ref020" ref-type="bibr">20</xref>]. In a 2012 study in Beijing (n = 400) synthetic drug use was associated with 3-fold greater odds of HIV infection [<xref rid="pone.0200816.ref016" ref-type="bibr">16</xref>]. A seven-city study completed in 2013 (n = 3,830) found higher HIV prevalence among users compared to non-users (12% versus 8%) [<xref rid="pone.0200816.ref015" ref-type="bibr">15</xref>]. In its larger companion study (n = 4,496) conducted in the same seven cities by the same research team also in 2013, 2-fold higher odds of recent HIV infection was found among MSM who had used synthetic drugs in the prior 6 months [<xref rid="pone.0200816.ref021" ref-type="bibr">21</xref>]. Finally, in 2014, another study in Beijing (n = 3,588) also found synthetic drug use to be associated with greater odds of HIV infection [<xref rid="pone.0200816.ref017" ref-type="bibr">17</xref>].</p><p>Taken together, this evidence clearly describes synthetic drug-using MSM as a dual-risk key population in China that is very vulnerable to HIV infection. While relatively new to China, the combination of synthetic drug use and high-risk sexual behavior by MSM is not new globally [<xref rid="pone.0200816.ref011" ref-type="bibr">11</xref>], and in fact, has become so common that it has been given names: &#x0201c;party-and-play&#x0201d; in North America and Australia, and &#x0201c;chemsex&#x0201d; in the remainder of the West as well as parts of southern Asia and central Europe [<xref rid="pone.0200816.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0200816.ref010" ref-type="bibr">10</xref>]. Well-documented on four continents [<xref rid="pone.0200816.ref005" ref-type="bibr">5</xref>&#x02013;<xref rid="pone.0200816.ref008" ref-type="bibr">8</xref>], synthetic drug use and high-risk sexual behavior has been consistently linked with HIV infection in MSM communities and is a serious global public health problem.</p><p>Between the time our study was conducted and our manuscript was submitted for publication, several additional, similar studies have been published. A large cross-sectional survey conducted in 2013 in Beijing found prevalence of recent (last 3 months) substance use to be 28%, nearly all reporting popper use, and substance users had higher odds of sexual risk behaviors including condomless anal intercourse (receptive and insertive), greater than 10 male sex partners lifetime, and multiple male partners in the past 3 months. Substance use was also associated with greater odds of HIV infection [<xref rid="pone.0200816.ref023" ref-type="bibr">23</xref>]. A nationwide, online, cross-sectional survey in 2014 found a 77% prevalence of lifetime synthetic drug use, and a 21% prevalence of popper use in the prior 12 months. Poppers users were more likely to have engaged in group sex in the prior 3 months and more likely to have had an HIV test [<xref rid="pone.0200816.ref018" ref-type="bibr">18</xref>]. A cross-sectional study in Nanjing (2014&#x02013;2015) found lifetime popper use prevalence of as high as 28% and 1.7-fold greater odds of HIV infection among popper users [<xref rid="pone.0200816.ref024" ref-type="bibr">24</xref>]. A small survey conducted in 2016 among MSM in Tianjin found prevalence of recent (last 6 months) substance use to be approximately 100%, with recent popper use at 98%. Among popper users, more than 85% reported increased sexual desire and pleasure after using and nearly 60% reported prolonged duration of sexual activity after using [<xref rid="pone.0200816.ref025" ref-type="bibr">25</xref>].</p><p>So, how do we meet the challenge of HIV prevention among the synthetic drug-using MSM population? Modeling work suggests that substantial modification of high-risk sexual behavior among MSM is insufficient to drive a meaningful reduction in HIV transmission [<xref rid="pone.0200816.ref003" ref-type="bibr">3</xref>]. This is supported by a recent meta-analysis of studies among MSM in China, which found that although education and behavioral interventions had improved consistent condom use, HIV/AIDS knowledge, and testing uptake, it had not been enough to reduce HIV prevalence [<xref rid="pone.0200816.ref026" ref-type="bibr">26</xref>]. Instead, due to already-high HIV prevalence in MSM communities, high transmission probability, and force of infection, biological interventions that successfully reduce infectiousness are far more likely to curb the growth of the HIV epidemic in this population [<xref rid="pone.0200816.ref003" ref-type="bibr">3</xref>]. Thus, HIV pre-exposure prophylaxis (PrEP), frequent testing (including self-testing), as well as immediate ART for infected individuals with counseling and adherence support should be implemented along with increased or improved programs targeting education and behavior. However, careful implementation of these interventions will be critical since the details of how these interventions are implemented are necessarily highly contextual [<xref rid="pone.0200816.ref027" ref-type="bibr">27</xref>].</p><p>For MSM in China, these programs must be customized to fit within their unique lifestyles (i.e., be easy and convenient), to meet their needs for prevention of stigma and discrimination (i.e., ensure privacy and confidentiality), and to reach them at the gateway to this part of their lives (i.e., via the internet and social media). Development and delivery of a comprehensive package of PrEP, high-frequency testing including self-testing, immediate treatment, and on-going counseling and adherence support interventions that is easy, convenient, private, confidential, and demand-driven via internet and social media environments frequented by the MSM community is urgently needed. Additionally, more must be done to educate MSM on the dangers of synthetic drug use, especially popper use, and China should strongly consider regulating poppers such that they clearly display warnings regarding their dangerous effects.</p></sec><sec id="sec019"><title>Limitations</title><p>Our study had some limitations. First, causal relationships cannot be assessed because of the cross-sectional study design. Second, the study only recruited among those who attended study CBOs to receive HIV counseling and testing services thus subjecting it to selection bias. Third, since poppers are legal in China, it is possible that their use relative to other synthetic drugs was overestimated due to social desirability and miss-classification bias. Fourth, there may have been other, unmeasured factors (e.g., alcohol and/or tobacco use) that contributed to the association between HIV infection and synthetic drug use in our study population. Lastly, there remains substantial stigma in China toward MSM and toward drug users and therefore, other participant responses may have also been subject to social desirability bias. However, considerable effort was made to prevent this by involving MSM CBO staff members in recruitment and interviewing, conducting interviews privately, assuring participants of data confidentiality, and ensuring that the questionnaire was well designed and interviewers well trained.</p></sec></sec><sec sec-type="conclusions" id="sec020"><title>Conclusions</title><p>In conclusion, our findings of synthetic drug use prevalence of nearly 40% among urban Chinese MSM, and a 2-fold greater probability of HIV-positive serostatus for this group, provide strong evidence of the pressing need of a carefully-designed and well-implemented package of biological prevention measures for this key, dual-risk population in China. Furthermore, there is now a wealth of observational evidence supporting these findings. Hence, prospective study intended to gain an understanding causality is now very much needed. Prevalence of HIV among urban Chinese MSM is already known to be on the rise [<xref rid="pone.0200816.ref013" ref-type="bibr">13</xref>], some reports putting prevalence figures at nearly 20% in some cities [<xref rid="pone.0200816.ref028" ref-type="bibr">28</xref>]. China must swiftly and effectively work to deflect the trajectory of its HIV epidemic among MSM, especially among those who use synthetic drugs, if it is to meet the UNAIDS 90-90-90 goals [<xref rid="pone.0200816.ref029" ref-type="bibr">29</xref>], and to eventually bring its HIV epidemic under control.</p></sec><sec sec-type="supplementary-material" id="sec021"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0200816.s001"><label>S1 Data</label><caption><title>All data.</title><p>(RAR)</p></caption><media xlink:href="pone.0200816.s001.rar"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors are grateful to all study subjects for their participation. We further appreciate all CBO staff members who helped with recruitment and data collection for our study. We also thank the following organizations for their support in organizing and implementing this study: Beijing CDC, Tianjin CDC, Changchun CDC, Heilongjiang Provincial CDC, Shanghai CDC, Jiangsu Provincial CDC, Zhejiang Provincial CDC, Hubei Provincial CDC, Guangzhou CDC, Shenzhen CDC, Nanning CDC, Chengdu CDC, Chongqing CDC, Yunnan Provincial CDC, Shanxi Provincial CDC, and Xinjiang Uyghur Autonomous Region CDC.</p><sec id="sec022"><title>Disclaimer</title><p>The opinions expressed herein reflect the collective views of the co-authors and do not necessarily represent the official position of the National Center for AIDS/STD Control and Prevention, China CDC.</p></sec></ack><ref-list><title>References</title><ref id="pone.0200816.ref001"><label>1</label><mixed-citation publication-type="other">UNAIDS. Prevention Gap Report Geneva: UNAIDS; 2016 [cited 2017 07 January]. <ext-link ext-link-type="uri" xlink:href="http://www.unaids.org/sites/default/files/media_asset/2016-prevention-gap-report_en.pdf">http://www.unaids.org/sites/default/files/media_asset/2016-prevention-gap-report_en.pdf</ext-link>.</mixed-citation></ref><ref id="pone.0200816.ref002"><label>2</label><mixed-citation publication-type="other">UNAIDS. The Gap Report Geneva: UNAIDS; 2014 [cited 2017 07 January]. <ext-link ext-link-type="uri" xlink:href="http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf">http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf</ext-link>.</mixed-citation></ref><ref id="pone.0200816.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Beyrer</surname><given-names>C</given-names></name>, <name><surname>Baral</surname><given-names>SD</given-names></name>, <name><surname>van Griensven</surname><given-names>F</given-names></name>, <name><surname>Goodreau</surname><given-names>SM</given-names></name>, <name><surname>Chariyalertsak</surname><given-names>S</given-names></name>, <name><surname>Wirtz</surname><given-names>AL</given-names></name>, <etal>et al</etal>
<article-title>Global epidemiology of HIV infection in men who have sex with men</article-title>. <source>Lancet</source>. <year>2012</year>;<volume>380</volume>(<issue>9839</issue>):<fpage>367</fpage>&#x02013;<lpage>77</lpage>. Epub 2012/07/24. <pub-id pub-id-type="doi">10.1016/S0140-6736(12)60821-6</pub-id> .<?supplied-pmid 22819660?><pub-id pub-id-type="pmid">22819660</pub-id></mixed-citation></ref><ref id="pone.0200816.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Beyrer</surname><given-names>C</given-names></name>, <name><surname>Baral</surname><given-names>SD</given-names></name>, <name><surname>Collins</surname><given-names>C</given-names></name>, <name><surname>Richardson</surname><given-names>ET</given-names></name>, <name><surname>Sullivan</surname><given-names>PS</given-names></name>, <name><surname>Sanchez</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>The global response to HIV in men who have sex with men</article-title>. <source>Lancet</source>. <year>2016</year>;<volume>388</volume>(<issue>10040</issue>):<fpage>198</fpage>&#x02013;<lpage>206</lpage>. Epub 2016/07/15. <pub-id pub-id-type="doi">10.1016/S0140-6736(16)30781-4</pub-id> .<?supplied-pmid 27411880?><pub-id pub-id-type="pmid">27411880</pub-id></mixed-citation></ref><ref id="pone.0200816.ref005"><label>5</label><mixed-citation publication-type="other">The EMIS Network. EMIS2010: The European men-who-have-sex-with-men internet survey. Findings from 38 countries Stockholm2013 [cited 2017 09 January]. <ext-link ext-link-type="uri" xlink:href="http://ecdc.europa.eu/en/publications/Publications/EMIS-2010-european-men-who-have-sex-with-men-survey.pdf">http://ecdc.europa.eu/en/publications/Publications/EMIS-2010-european-men-who-have-sex-with-men-survey.pdf</ext-link>.</mixed-citation></ref><ref id="pone.0200816.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Colfax</surname><given-names>G</given-names></name>, <name><surname>Coates</surname><given-names>TJ</given-names></name>, <name><surname>Husnik</surname><given-names>MJ</given-names></name>, <name><surname>Huang</surname><given-names>Y</given-names></name>, <name><surname>Buchbinder</surname><given-names>S</given-names></name>, <name><surname>Koblin</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men</article-title>. <source>J Urban Health</source>
<year>2005</year>;<volume>82</volume>(<issue>Suppl 1</issue>):<fpage>i62</fpage>&#x02013;<lpage>70</lpage>. 105.<pub-id pub-id-type="pmid">15738319</pub-id></mixed-citation></ref><ref id="pone.0200816.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Lea</surname><given-names>T</given-names></name>, <name><surname>Prestage</surname><given-names>G</given-names></name>, <name><surname>Mao</surname><given-names>L</given-names></name>, <name><surname>Zablotska</surname><given-names>I</given-names></name>, <name><surname>Wit</surname><given-names>Jd</given-names></name>, <name><surname>Holt</surname><given-names>M</given-names></name>. <article-title>Trends in drug use among gay and bisexual men in Sydney, Melbourne and Queensland, Australia</article-title>. <source>Drug Alcohol Rev</source>. <year>2013</year>;<volume>32</volume>(<issue>1</issue>):<fpage>39</fpage>&#x02013;<lpage>46</lpage>. 106. <pub-id pub-id-type="doi">10.1111/j.1465-3362.2012.00494.x</pub-id>
<?supplied-pmid 22882678?><pub-id pub-id-type="pmid">22882678</pub-id></mixed-citation></ref><ref id="pone.0200816.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Wei</surname><given-names>C</given-names></name>, <name><surname>Guadamuz</surname><given-names>TE</given-names></name>, <name><surname>Lim</surname><given-names>SH</given-names></name>, <name><surname>Huang</surname><given-names>Y</given-names></name>, <name><surname>Koe</surname><given-names>S</given-names></name>. <article-title>Patterns and levels of illicit drug use among men who have sex with men in Asia</article-title>. <source>Drug Alcohol Depend</source>. <year>2012</year>;<volume>120</volume>:<fpage>246</fpage>&#x02013;<lpage>9</lpage>. 107. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2011.07.016</pub-id>
<?supplied-pmid 21831535?><pub-id pub-id-type="pmid">21831535</pub-id></mixed-citation></ref><ref id="pone.0200816.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Melendez-Torez</surname><given-names>GJ</given-names></name>, <name><surname>Bourne</surname><given-names>A</given-names></name>. <article-title>Illicit drug use and its association with sexual risk behavior among MSM: more questions than answers?</article-title>
<source>Curr Opin Infect Dis</source>. <year>2016</year>;<volume>29</volume>:<fpage>58</fpage>&#x02013;<lpage>63</lpage>. 108. <pub-id pub-id-type="doi">10.1097/QCO.0000000000000234</pub-id>
<?supplied-pmid 26694620?><pub-id pub-id-type="pmid">26694620</pub-id></mixed-citation></ref><ref id="pone.0200816.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>McCall</surname><given-names>H</given-names></name>, <name><surname>Adams</surname><given-names>N</given-names></name>, <name><surname>Mason</surname><given-names>D</given-names></name>, <name><surname>Willis</surname><given-names>J</given-names></name>. <article-title>What is chemsex and why does it matter?</article-title>
<source>BMJ</source>. <year>2015</year>;<volume>351</volume>:<fpage>h5790</fpage> 109. <pub-id pub-id-type="doi">10.1136/bmj.h5790</pub-id>
<?supplied-pmid 26537832?><pub-id pub-id-type="pmid">26537832</pub-id></mixed-citation></ref><ref id="pone.0200816.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Vu</surname><given-names>NT</given-names></name>, <name><surname>Maher</surname><given-names>L</given-names></name>, <name><surname>Zablotska</surname><given-names>I</given-names></name>. <article-title>Amphetamine-type stimulants and HIV infection among men who have sex with men: implications on HIV research and prevention from a systematic review and meta-analysis</article-title>. <source>J Int AIDS Soc</source>. <year>2015</year>;<volume>18</volume>:<fpage>19273</fpage> Epub 2015 Jan 16. <pub-id pub-id-type="doi">10.7448/IAS.18.1.19273</pub-id> eCollection 2015. 110. <?supplied-pmid 25609214?><pub-id pub-id-type="pmid">25609214</pub-id></mixed-citation></ref><ref id="pone.0200816.ref012"><label>12</label><mixed-citation publication-type="other">Office of China National Narcotics Control Commission. Annual Report on Drug Situation in China 2014. Beijing: 2015.</mixed-citation></ref><ref id="pone.0200816.ref013"><label>13</label><mixed-citation publication-type="book"><name><surname>Wu</surname><given-names>Z</given-names></name>. <source>HIV/AIDS in China- Beyond the Numbers</source>. <publisher-loc>Beijing, China</publisher-loc>: <publisher-name>People&#x02019;s Medical Publishing House</publisher-name>; <year>2016</year>.</mixed-citation></ref><ref id="pone.0200816.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Tang</surname><given-names>S</given-names></name>, <name><surname>Tang</surname><given-names>W</given-names></name>, <name><surname>Meyers</surname><given-names>K</given-names></name>, <name><surname>Chan</surname><given-names>P</given-names></name>, <name><surname>Chen</surname><given-names>Z</given-names></name>, <name><surname>Tucker</surname><given-names>JD</given-names></name>. <article-title>HIV epidemiology and responses among men who have sex with men and transgender individuals in China: a scoping review</article-title>. <source>BMC Infect Dis</source>. <year>2016</year>;<volume>16</volume>(<issue>1</issue>):<fpage>588</fpage> Epub 2016/10/22. <pub-id pub-id-type="doi">10.1186/s12879-016-1904-5</pub-id> .<?supplied-pmid 27765021?><pub-id pub-id-type="pmid">27765021</pub-id></mixed-citation></ref><ref id="pone.0200816.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>JJ</given-names></name>, <name><surname>Zhang</surname><given-names>C</given-names></name>, <name><surname>Hu</surname><given-names>QH</given-names></name>, <name><surname>Chu</surname><given-names>ZX</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>YZ</given-names></name>, <etal>et al</etal>
<article-title>Recreational drug use and risks of HIV and sexually transmitted infections among Chinese men who have sex with men: Mediation through multiple sexual partnerships</article-title>. <source>BMC Infect Dis</source>. <year>2014</year>;<volume>14</volume>:<fpage>642</fpage> Epub 2014/12/03. <pub-id pub-id-type="doi">10.1186/s12879-014-0642-9</pub-id> .<?supplied-pmid 25443542?><pub-id pub-id-type="pmid">25443542</pub-id></mixed-citation></ref><ref id="pone.0200816.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>D</given-names></name>, <name><surname>Yang</surname><given-names>X</given-names></name>, <name><surname>Zhang</surname><given-names>Z</given-names></name>, <name><surname>Qi</surname><given-names>X</given-names></name>, <name><surname>Ruan</surname><given-names>Y</given-names></name>, <name><surname>Jia</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Nitrite inhalants use and HIV infection among men who have sex with men in China</article-title>. <source>BioMed Res Int</source>. <year>2014</year>:<fpage>365261</fpage> 117. <pub-id pub-id-type="doi">10.1155/2014/365261</pub-id>
<?supplied-pmid 24800219?><pub-id pub-id-type="pmid">24800219</pub-id></mixed-citation></ref><ref id="pone.0200816.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>H</given-names></name>, <name><surname>Tenga</surname><given-names>T</given-names></name>, <name><surname>Lu</surname><given-names>H</given-names></name>, <name><surname>Zhao</surname><given-names>Y</given-names></name>, <name><surname>Liu</surname><given-names>H</given-names></name>, <name><surname>Yin</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Poppers use and risky sexual behaviors among men who have sex with men in Beijing, China</article-title>. <source>Drug Alcohol Depend</source>. <year>2016</year>;<volume>160</volume>:<fpage>42</fpage>&#x02013;<lpage>8</lpage>. 120. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2015.11.037</pub-id>
<?supplied-pmid 26796594?><pub-id pub-id-type="pmid">26796594</pub-id></mixed-citation></ref><ref id="pone.0200816.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>P</given-names></name>, <name><surname>Tang</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>C</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Best</surname><given-names>J</given-names></name>, <name><surname>Tangthanasup</surname><given-names>TM</given-names></name>, <etal>et al</etal>
<article-title>Recreational drug use among Chinese MSM and transgender individuals: results from a national online cross-sectional study</article-title>. <source>PLoS One</source>. <year>2017</year>;<volume>12</volume>(<issue>1</issue>):<fpage>e0170024</fpage> 121. <pub-id pub-id-type="doi">10.1371/journal.pone.0170024</pub-id>
<?supplied-pmid 28107391?><pub-id pub-id-type="pmid">28107391</pub-id></mixed-citation></ref><ref id="pone.0200816.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Zheng</surname><given-names>J</given-names></name>, <name><surname>Zhao</surname><given-names>J</given-names></name>, <name><surname>He</surname><given-names>J</given-names></name>, <name><surname>Zhang</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Club Drugs and HIV/STD Infection: An Exploratory Analysis among Men Who Have Sex with Men in Changsha, China</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>5</issue>):<fpage>e0126320</fpage> Epub 2015/05/08. <pub-id pub-id-type="doi">10.1371/journal.pone.0126320</pub-id> .<?supplied-pmid 25950912?><pub-id pub-id-type="pmid">25950912</pub-id></mixed-citation></ref><ref id="pone.0200816.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>JJ</given-names></name>, <name><surname>Qian</surname><given-names>HZ</given-names></name>, <name><surname>Chu</surname><given-names>ZX</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Hu</surname><given-names>QH</given-names></name>, <name><surname>Jiang</surname><given-names>YJ</given-names></name>, <etal>et al</etal>
<article-title>Recreational drug use among Chinese men who have sex with men: a risky combination with unprotected sex for acquiring HIV infection</article-title>. <source>Biomed Res Int</source>. <year>2014</year>;<volume>2014</volume>:<fpage>725361</fpage> Epub 2014/05/16. <pub-id pub-id-type="doi">10.1155/2014/725361</pub-id> .<?supplied-pmid 24829916?><pub-id pub-id-type="pmid">24829916</pub-id></mixed-citation></ref><ref id="pone.0200816.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>JJ</given-names></name>, <name><surname>Tang</surname><given-names>WM</given-names></name>, <name><surname>Zou</surname><given-names>HC</given-names></name>, <name><surname>Mahapatra</surname><given-names>T</given-names></name>, <name><surname>Hu</surname><given-names>QH</given-names></name>, <name><surname>Fu</surname><given-names>GF</given-names></name>, <etal>et al</etal>
<article-title>High HIV incidence epidemic among men who have sex with men in china: results from a multi-site cross-sectional study</article-title>. <source>Infect Dis Poverty</source>. <year>2016</year>;<volume>5</volume>(<issue>1</issue>):<fpage>82</fpage> Epub 2016/09/07. <pub-id pub-id-type="doi">10.1186/s40249-016-0178-x</pub-id> .<?supplied-pmid 27593703?><pub-id pub-id-type="pmid">27593703</pub-id></mixed-citation></ref><ref id="pone.0200816.ref022"><label>22</label><mixed-citation publication-type="book"><collab>Chinese Center for Disease Control and Prevention</collab>. <source>National Guideline for Detection of HIV/AIDS (revision in 2009)</source>. <publisher-loc>Beijing, China</publisher-loc>: <year>2009</year>.</mixed-citation></ref><ref id="pone.0200816.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>C</given-names></name>, <name><surname>Qian</surname><given-names>HZ</given-names></name>, <name><surname>Yin</surname><given-names>L</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Strauss</surname><given-names>SM</given-names></name>, <name><surname>Ruan</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Sexual Behaviors Linked to Drug and Alcohol Use Among Men Who Have Sex With Men in China</article-title>. <source>Subst Use Misuse</source>. <year>2016</year>;<volume>51</volume>(<issue>14</issue>):<fpage>1821</fpage>&#x02013;<lpage>30</lpage>. Epub 2016/09/09. <pub-id pub-id-type="doi">10.1080/10826084.2016.1197264</pub-id> .<?supplied-pmid 27608264?><pub-id pub-id-type="pmid">27608264</pub-id></mixed-citation></ref><ref id="pone.0200816.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>ZP</given-names></name>, <name><surname>Zhang</surname><given-names>M</given-names></name>, <name><surname>Xu</surname><given-names>YY</given-names></name>, <name><surname>Xu</surname><given-names>WJ</given-names></name>, <name><surname>Liu</surname><given-names>L</given-names></name>, <name><surname>Wu</surname><given-names>SS</given-names></name>, <etal>et al</etal> [<article-title>Cross-sectional surveys on the use of recreational drug nitrous-acid-ester rush-poppers in men who have sex with men, Nanjing</article-title>]. <source>Zhonghua Liu Xing Bing Xue Za Zhi</source>. <year>2017</year>;<volume>38</volume>(<issue>2</issue>):<fpage>189</fpage>&#x02013;<lpage>93</lpage>. Epub 2017/02/25. <pub-id pub-id-type="doi">10.3760/cma.j.issn.0254-6450.2017.02.011</pub-id> .<?supplied-pmid 28231664?><pub-id pub-id-type="pmid">28231664</pub-id></mixed-citation></ref><ref id="pone.0200816.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Shan</surname><given-names>D</given-names></name>, <name><surname>Wu</surname><given-names>D</given-names></name>, <name><surname>Liu</surname><given-names>L</given-names></name>, <name><surname>Liu</surname><given-names>H</given-names></name>, <name><surname>Yin</surname><given-names>WY</given-names></name>, <name><surname>Yu</surname><given-names>MH</given-names></name>, <etal>et al</etal> [<article-title>A survey on high-risk behaviors and HIV infection among men having sex with men who use drugs in Tianjin in 2016</article-title>]. <source>Zhonghua Yu Fang Yi Xue Za Zhi</source>. <year>2017</year>;<volume>51</volume>(<issue>8</issue>):<fpage>718</fpage>&#x02013;<lpage>22</lpage>. Epub 2017/08/03. <pub-id pub-id-type="doi">10.3760/cma.j.issn.0253-9624.2017.08.011</pub-id> .<?supplied-pmid 28763921?><pub-id pub-id-type="pmid">28763921</pub-id></mixed-citation></ref><ref id="pone.0200816.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>H</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Dahiya</surname><given-names>K</given-names></name>, <name><surname>Qian</surname><given-names>H</given-names></name>, <name><surname>Fan</surname><given-names>W</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Effectiveness of HIV risk reduction interventions among men who have sex with men in China: a systematic review and meta-analysis</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>8</volume>(<issue>8</issue>):<fpage>e72747</fpage>. 123.</mixed-citation></ref><ref id="pone.0200816.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Lambdin</surname><given-names>BH</given-names></name>, <name><surname>Cheng</surname><given-names>B</given-names></name>, <name><surname>Peter</surname><given-names>T</given-names></name>, <name><surname>Mbwambo</surname><given-names>J</given-names></name>, <name><surname>Apollo</surname><given-names>T</given-names></name>, <name><surname>Dunbar</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Implementing implementation science: an approach for HIV prevention, care and treatment programs</article-title>. <source>Curr HIV Res</source>. <year>2015</year>;<volume>13</volume>:<fpage>244</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.2174/1570162X1303150506185423</pub-id>
<?supplied-pmid 25986374?><pub-id pub-id-type="pmid">25986374</pub-id></mixed-citation></ref><ref id="pone.0200816.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>Z</given-names></name>, <name><surname>Xu</surname><given-names>J</given-names></name>, <name><surname>Liu</surname><given-names>E</given-names></name>, <name><surname>Mao</surname><given-names>Y</given-names></name>, <name><surname>Xiao</surname><given-names>Y</given-names></name>, <name><surname>Sun</surname><given-names>X</given-names></name>, <etal>et al</etal>
<article-title>HIV and syphilis prevalence among men who have sex with men: a cross-sectional survey of 61 cities in China</article-title>. <source>Clin Infect Dis</source>. <year>2013</year>;<volume>57</volume>(<issue>2</issue>):<fpage>298</fpage>&#x02013;<lpage>309</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cit210</pub-id>
<?supplied-pmid 23580732?><pub-id pub-id-type="pmid">23580732</pub-id></mixed-citation></ref><ref id="pone.0200816.ref029"><label>29</label><mixed-citation publication-type="other">UNAIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic Geneva2014 [cited 2017 28 January]. <ext-link ext-link-type="uri" xlink:href="http://www.unaids.org/en/resources/documents/2014/90-90-90">http://www.unaids.org/en/resources/documents/2014/90-90-90</ext-link>.</mixed-citation></ref></ref-list></back></article>